KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Treasury Shares (2021 - 2025)

Recursion Pharmaceuticals (RXRX) has disclosed Treasury Shares for 5 consecutive years, with $27.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Treasury Shares rose 0.68% year-over-year to $27.5 million, compared with a TTM value of $27.5 million through Dec 2025, up 0.68%, and an annual FY2025 reading of $27.5 million, up 0.68% over the prior year.
  • Treasury Shares was $27.5 million for Q4 2025 at Recursion Pharmaceuticals, down from $30.6 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $30.6 million in Q3 2025 and bottomed at $76762.0 in Q2 2021.
  • Average Treasury Shares over 5 years is $14.1 million, with a median of $15.6 million recorded in 2024.
  • The sharpest move saw Treasury Shares surged 9055.72% in 2022, then increased 0.68% in 2025.
  • Year by year, Treasury Shares stood at $478136.0 in 2021, then surged by 1341.96% to $6.9 million in 2022, then surged by 120.81% to $15.2 million in 2023, then skyrocketed by 79.35% to $27.3 million in 2024, then rose by 0.68% to $27.5 million in 2025.
  • Business Quant data shows Treasury Shares for RXRX at $27.5 million in Q4 2025, $30.6 million in Q3 2025, and $21.7 million in Q2 2025.